More importantly, the T cell reconstitution after ASCT is skewed toward CD8 T cells and provides a favorable CD8 effector T cell (Teff) to Treg ratio (20, 21) which often underpins effective anti-tumor immunity. This evidence concerns the gene CD8A and neoplasm.